Focal nodular hyperplasia: central scar enhancement pattern using Gadoxetate Disodium.
OBJECTIVE
To illustrate the unusual enhancement pattern of the focal nodular hyperplasia central scar using Gadoxetate Disodium.


METHODS
Over a 10-month period, six patients, with a total of seven focal nodular hyperplasia lesions with typical central scar, had MRI of the liver using Gadoxetate Disodium (Eovist, Bayer HealthCare Pharmaceuticals Inc., Wayne, NJ). Four of the six patients had a prior Gadobenate Dimeglumine (Multihance, Bracco Diagnostics Inc., Princeton, NJ) -enhanced MRI of the liver performed within the previous year. The dynamic enhancement pattern of the central scar on the 10 liver MRIs was independently analyzed by two abdominal imaging radiologists who were blinded to the contrast agent used.


RESULTS
On the Gadoxetate Disodium-enhanced MRIs and during the arterial phase, 1-min, 2-min, and 3-min delay, none of the central scars demonstrated enhancement. However, all four of the lesions that were previously scanned using Gadobenate Dimeglumine demonstrated typical enhancement after a 3-min delay.


CONCLUSIONS
On Gadoxetate Disodium-enhanced MRIs of the liver, the central scar of focal nodular hyperplasia lesions does not typically demonstrate delayed enhancement.
Karam
Adib R
AR
Radiology Department, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA. karama@ummhc.org
Shankar
Sridhar
S
Surapaneni
Padmaja
P
Kim
Young H
YH
Hussain
Sarwat
S
D000328:Adult; D003287:Contrast Media / Q000494:pharmacology*; D005260:Female; D020518:Focal Nodular Hyperplasia / Q000473:pathology*; D019786:Gadolinium DTPA / Q000494:pharmacology*; D006801:Humans; D006965:Hyperplasia; D007091:Image Processing, Computer-Assisted; D008099:Liver / Q000473:pathology*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008536:Meglumine / Q000494:pharmacology; D008875:Middle Aged; D013997:Time Factors
D003287:Contrast Media; C073590:gadolinium ethoxybenzyl DTPA; D008536:Meglumine; D019786:Gadolinium DTPA